A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
← catalyst calendarNCT06798298 · readout in 5,051 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-10 | actual | When the study began enrolling |
| Primary completion | 2040-06-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2040-06-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Long Term Safety Following GM T Cell Therapy
Intervention
- Genetic: Non-interventional
Primary outcomes
what the primary-completion date above is the date OFIncidence of delayed adverse events considered at least possibly related to prior gene modified T cell therapy
measured Up to 15 years
Persistence of gene modified T cells
measured Up to 15 years
Analysis of vector integration sites
measured Up to 15 years
Incidence of RCL
measured Up to 15 years
Disease progression status
measured Up to 15 years
Date of disease progression
measured Up to 15 years
Survival status
measured Up to 15 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed